ABSTRACT
BACKGROUND: In response to the COVID-19 pandemic, endoscopic societies initially recommended reduction of endoscopic procedures. In particular non-urgent endoscopies should be postponed. However, this might lead to unnecessary delay in diagnosing gastrointestinal conditions. METHODS: Retrospectively we analysed the gastrointestinal endoscopies performed at the Central Endoscopy Unit of Saarland University Medical Center during seven weeks from 23 March to 10 May 2020 and present our real-world single-centre experience with an individualized rtPCR-based pre-endoscopy SARS-CoV-2 testing strategy. We also present our experience with this strategy in 2021. RESULTS: Altogether 359 gastrointestinal endoscopies were performed in the initial period. The testing strategy enabled us to conservatively handle endoscopy programme reduction (44% reduction as compared 2019) during the first wave of the COVID-19 pandemic. The results of COVID-19 rtPCR from nasopharyngeal swabs were available in 89% of patients prior to endoscopies. Apart from six patients with known COVID-19, all other tested patients were negative. The frequencies of endoscopic therapies and clinically significant findings did not differ between patients with or without SARS-CoV-2 tests. In 2021 we were able to unrestrictedly perform all requested endoscopic procedures (> 5000 procedures) by applying the rtPCR-based pre-endoscopy SARS-CoV-2 testing strategy, regardless of next waves of COVID-19. Only two out-patients (1893 out-patient procedures) were tested positive in the year 2021. CONCLUSION: A structured pre-endoscopy SARS-CoV-2 testing strategy is feasible in the clinical routine of an endoscopy unit. rtPCR-based pre-endoscopy SARS-CoV-2 testing safely allowed unrestricted continuation of endoscopic procedures even in the presence of high incidence rates of COVID-19. Given the low frequency of positive tests, the absolute effect of pre-endoscopy testing on viral transmission may be low when FFP-2 masks are regularly used.
Subject(s)
COVID-19 Testing/statistics & numerical data , COVID-19/diagnosis , Endoscopy, Gastrointestinal/statistics & numerical data , Preoperative Care/statistics & numerical data , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Female , Germany , Humans , Infant , Infant, Newborn , Male , Middle Aged , Pandemics , Retrospective Studies , SARS-CoV-2 , Young AdultABSTRACT
Binuclear rare earth complexes Ln2L3phen2 (LnIII = NdIII, SmIII, EuIII, TbIII, DyIII, YbIII and YIII) with bis-CAPh type ligand - tetramethyl N,N'-(2,2,3,3,4,4-hexafluoro-1,5-dioxopentane-1,5-diyl)bis(phosphoramidate) (H2L) and 1,10-phenanthroline (phen) were synthesized and characterized by elemental analysis, IR, NMR, absorption and luminescence spectroscopy. Luminescence measurements were performed for all the complexes in solid state and for the EuIII, TbIII and YIII complexes - in solution in DMSO as well. The effective energy transfer from organic ligands to LnIII ions strongly sensitizes the LnIII ions emission and under excitation by UV light, the complexes exhibited bright characteristic emission of lanthanide metal centers. It was found that the energy level of the ligands lowest triplet state in the complexes matches better to resonance level of EuIII rather than TbIII ion. Depending on temperature the emission decay times of solid europium and terbium complexes were in the range of 1.5-2.0 ms. In solid state at room temperature the EuIII complex possess intense luminescence with very high intrinsic quantum yield 91% and decay time equal 1.88 ms.
Subject(s)
Zika Virus Infection/diagnosis , Zika Virus/isolation & purification , Antibodies, Neutralizing/blood , Antibodies, Neutralizing/immunology , Antibodies, Viral/analysis , Germany , Humans , Immunoglobulin G/blood , Immunoglobulin M/blood , Male , Real-Time Polymerase Chain Reaction , Thailand , Zika Virus/genetics , Zika Virus/immunology , Zika Virus Infection/blood , Zika Virus Infection/virologyABSTRACT
We report the case of a patient with suspected ulcerating necrotizing herpetic stromal keratitis who showed no improvement despite intensive (amongst others antiherpetic) topical and systemic therapy. The ulcer healed following amniotic membrane transplantation and penetrating excimer laser keratoplasty was performed to improve visual acuity. The excision showed deep stromal proof of herpes simplex virus (HSV) type 1 antigens.
Subject(s)
Acyclovir/therapeutic use , Amnion/transplantation , Biological Dressings , Keratitis, Herpetic/pathology , Keratitis, Herpetic/surgery , Keratoplasty, Penetrating/methods , Laser Therapy/methods , Aged , Antiviral Agents/therapeutic use , Combined Modality Therapy/methods , Humans , Male , Treatment Failure , Treatment OutcomeABSTRACT
BACKGROUND: Primary corneal graft failure (PCGF) after penetrating keratoplasty (PKP) despite good endothelial cell count of the transplant in organ culture rarely occurs in young patients. A herpes simplex virus type I (HSV-1) infection (transmission through the donor or reactivation by the patient) can lead to PCGF. METHODS: We report on a 43-year-old man with pellucid marginal corneal degeneration and neurodermitis, who was underwent penetrating keratoplasty (PKP) on the left eye after acute corneal hydrops in both eyes. A repeat keratoplasty (re-PKP) had to be performed 15 days after the first PKP due to a primary graft failure. A re-re-PKP with simultaneous amniotic membrane transplantation (as a patch) and partial lateral tarsorrhaphy became necessary 4 months after the re-PKP due to melting on the edge of the graft with persistent epithelial defects. RESULTS: After intensive cooperation between ophthalmologists and pathologists the histopathological findings showed keratocytes which reacted immunohistochemically positive for HSV-1 antigens in the deep corneal stroma of both corneal grafts. The excised own cornea of the patient was histopathologically negative but the DNA-PCR for HSV-1 was weakly positive. After adequate topical and systemic antiviral therapy the third graft has remained clear for 12 months. CONCLUSION: In cases of PCGF after normal risk corneal transplantation the possibility of HSV infection should always be considered. After confirmation of the diagnosis with the help of the immunohistochemical tests and/or PCR, an adequate treatment with antiviral medication (acyclovir tablets 2 × 400 mg for more than 1 year) should be administered to the patient after repeat PKP.
Subject(s)
Corneal Transplantation , Keratitis, Herpetic/transmission , Keratoplasty, Penetrating , Postoperative Complications/diagnosis , Postoperative Complications/surgery , Adult , Antigens, Viral/analysis , Cooperative Behavior , Corneal Keratocytes/pathology , Corneal Keratocytes/virology , Follow-Up Studies , Graft Rejection/diagnosis , Graft Rejection/pathology , Graft Rejection/surgery , Herpes Simplex/immunology , Humans , Interdisciplinary Communication , Keratitis, Herpetic/diagnosis , Keratitis, Herpetic/pathology , Male , Postoperative Complications/pathology , ReoperationSubject(s)
Anus Neoplasms/prevention & control , Condylomata Acuminata/prevention & control , Evidence-Based Medicine , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/administration & dosage , Uterine Cervical Neoplasms/prevention & control , Adolescent , Anus Neoplasms/virology , Child , Female , Genital Neoplasms, Male/prevention & control , Genital Neoplasms, Male/virology , Germany , Human papillomavirus 11 , Human papillomavirus 16 , Human papillomavirus 18 , Human papillomavirus 6 , Humans , Immunization Schedule , Male , Papillomavirus Infections/virology , Risk Factors , Uterine Cervical Neoplasms/virology , Young AdultABSTRACT
Persistent infection with HPV 16 and 18 has been causally associated with the development of cervical cancer and its precursor lesions as well as with other carcinomas and their precursors, e.g. some vulvar and vaginal cancers. Furthermore HPV 6 and 11 are responsible for anogenital condylomata acuminata in more than 90% of cases. With the recently developed prophylactic bivalent (HPV 16 and 18) and quadrivalent (HPV 6, 11, 16 and 18) vaccines, it is possible to prevent infection of the cervical epithelium and other squamous epithelia, the development of premalignant lesions and, in the case of the quadrivalent vaccine, the development of condylomata acuminata. The following paper represents a summary of the full-text version of the German evidence-based Guidelines, including all evidence-based recommendations regarding the safety as well as the efficacy of the vaccines in preventing CIN, VIN/VaIN, genital warts and other HPV-associated lesions.
Subject(s)
Papillomavirus Infections/complications , Papillomavirus Infections/prevention & control , Papillomavirus Vaccines/immunology , Uterine Cervical Neoplasms/immunology , Uterine Cervical Neoplasms/prevention & control , Female , Humans , Papillomavirus Infections/immunology , Uterine Cervical Neoplasms/virologyABSTRACT
AIMS: To provide evidence that DNA-PCR diagnostics of oral pathogens based on standard sample collection by paper point insertion from the depth of the periodontal pocket can be replaced by a novel non-invasive collection method based on swab technique from the gingiva. METHODS AND RESULTS: In this study we compared the results from two collection methods performed in 35 patients with chronic adult periodontitis. Statistical analysis showed a highly significant association of diagnostic results between both collection techniques. CONCLUSIONS: The Pocket-out method represents a reliable alternative to the standard collection technique for PCR diagnosis of oral pathogens. SIGNIFICANCE AND IMPACT OF THE STUDY: Due to its simplicity and non-invasiveness, the Pocket-out collection could be performed in any physician office, or even by the patient himself. With respect to the putative association between periodontal disease and various systemic illnesses, this method could be integrated with various screening programs of oral pathogens.
Subject(s)
Bacteria, Anaerobic/isolation & purification , Bacterial Infections/diagnosis , DNA, Bacterial/isolation & purification , Periodontitis/diagnosis , Polymerase Chain Reaction/methods , Specimen Handling/methods , Adult , Bacteria, Anaerobic/classification , Bacteria, Anaerobic/genetics , Bacterial Infections/pathology , Chronic Disease , DNA, Bacterial/analysis , Gingiva/microbiology , Humans , Models, Anatomic , Mouth/microbiology , Periodontal Pocket/diagnosis , Periodontitis/microbiology , Periodontitis/pathology , Sensitivity and SpecificityABSTRACT
Outcomes for middle-aged and older individuals with HIV infection are poor, and are likely to be mediated by age-related differences in risks and resources (access to care, relationship with the provider, comorbid conditions, health habits, and changes brought about by aging). The goal of the Veterans Aging Cohort Three-Site Study (VACS 3) is to study the influence of age and mediating factors on outcomes with HIV in order to identify mutable mediators of poorer outcomes. VACS 3 is an observational, longitudinal study. Data sources include patient and provider surveys and electronic medical data collected at baseline and 12-month follow-up from the Infections Disease Clinics at three Veterans Affairs Medical Centers (Cleveland, OH, Houston, TX, and Manhattan, NY). Trained Survey Coordinators at each site determined which patients are HIV infected, obtained consent, and asked the patient to complete a questionnaire. The primary provider also completed a questionnaire. Twelve-month follow-up will be completed July 2001. Of all veterans with HIV seen in these clinics 85% (881) have consented and enrolled. Of the 881 corresponding provider surveys, 92% were completed. Mean age is 49; 55% are African-American; 38% of the sample were men who have sex with men; and less than 2% are women. Almost a third (32%) have been without a permanent address. Complimentary or alternative therapies are common as are the use of cigarettes, alcohol, and illicit drugs. The majority (87%) of the patients are taking multiple antiretroviral medications. The median CD4 count is 331 mm(3), and the median viral load was 714 copies/ml. There is substantial variation by site. Veterans with HIV infection have characteristics that will likely become more prevalent among HIV-infected persons in the United States: they are older, commonly suffer comorbid disease, and are members of minority populations. VACS 3 may help inform the design of future clinical interventions to improve outcomes for people aging with HIV.
Subject(s)
Aging/physiology , HIV Infections/epidemiology , HIV Infections/therapy , Outcome Assessment, Health Care , Veterans , Aged , Analysis of Variance , Chronic Disease , Female , HIV Infections/physiopathology , HIV Infections/psychology , Humans , Longitudinal Studies , Male , Middle Aged , Quality of Life , Research Design , Risk Factors , Statistics, Nonparametric , Surveys and Questionnaires , United States/epidemiologyABSTRACT
Qualitative in-person interviews with 114 older African Americans and whites with chronic illness were conducted to assess whether they thought of themselves as healthy or not healthy and the meanings associated with that assessment. The first and most frequently assigned attribute of healthy was the presence of functional capacities; for not healthy it was the presence of medical conditions or physical symptoms. While both African Americans and whites responded similarly regarding the assessment of whether they were healthy or not healthy, African Americans described the attributes associated with healthy or not healthy somewhat differently than whites. Also, both groups reported more varied meanings to the concept of 'healthy' than to 'not healthy', suggesting that 'healthy' may be a multidimensional construct more connected to ones' total life experiences than is 'not healthy'. This study concludes that social and cultural factors such as race, ethnicity or health experiences may influence how individuals perceive and describe their health status and the processes used in making these assessments.
ABSTRACT
This exploratory study of 205 older adults with chronic illness, of whom 55 enrolled in Medicare HMOs, examined the characteristics of those who enrolled, their experiences with managed care, and the differences between African Americans and whites in these domains. HMO enrollees were more likely to report their finances as inadequate; to have a high school education or less; and to have higher levels of social support. No significant differences by race were found in enrollment or in factors related to enrollment. Enrollees joined because of low premiums, enhanced HMO benefits, and pressure from employers providing retiree health benefits. The majority of enrollees reported positive experiences, however, more whites than African Americans reported negative experiences.